http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Plazomicin—a New Aminoglycoside—for Treating Complicated Urinary Tract Infections
라흐만 모하마드 세이더,Gazi Mohammad Al Amin,Shah Mohammad Anwar,Mohammad Ferdaus Azam,Fatema Akhter,Mohammad Rabiul Islam,고영상 대한미생물학회 2023 Journal of Bacteriology and Virology Vol.53 No.1
Plazomicin belongs to a new class of semisynthetic aminoglycosides that suppress bacterial protein synthesis. The US Food and Drug Administration has approved this antibacterial drug for use in adult patients with complicated urinary tract infections (cUTIs), such as pyelonephritis. The worldwide emergence of multidrug- resistant (MDR) organisms has become a significant health issue. It is a promising alternative to carbapenems or β-lactam/β-lactamase inhibitors for treating cUTIs caused by MDR Enterobacterales. Plazomicin is primarily designed to overcome the common resistance mechanisms of pathogens. It has also demonstrated good in vitro efficacy against various resistant gram-negative pathogens. Plazomicin inhibits bacterial protein synthesis and exhibits rapid bactericidal efficacy against numerous extended-spectrum beta-lactamase (ESBL) producing, aminoglycoside- resistant, and carbapenem-resistant bacterial isolates. Similar to other amin- oglycosides, plazomicin inhibits bacterial protein synthesis by attaching to the 30S ribosomal subunit of bacteria. Plazomicin also demonstrated a favorable minimum inhibitory concentration value compared to other aminoglycosides such as gentamicin, amikacin, and tobramycin. The commonly observed adverse effects of plazomicin include headache, hypertension, nausea, diarrhea, vomiting, and hypotension. In this review, we discuss the likelihood of using plazomicin to treat bacterial infections, focusing on its chemistry, mode of action pharmacokinetics, indications for treatment, adverse reactions, and safety profile.